3.43  0.17 (5.21%)		04-25 16:00
Open: 3.15 High: 3.44 Volume: 44,874		Pre. Close: 3.26 Low: 3.1 Market Cap: 39(M)

Short term
Mid term
Targets	6-month :	4.79	1-year :	5.6
Resists	First :	4.1	Second :	4.79
Pivot price	3.19
Supports	First :	3.21	Second :	2.67
MAs	MA(5) :	3.26	MA(20) :	3.23
	MA(100) :	3.64	MA(250) :	3.3
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	74.8	D(3) :	66.8
RSI	RSI(14): 50.8
52-week	High :	5.3	Low :	1.79

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ LNSR ] has closed Bollinger Bands are 69% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.44 - 3.46	3.46 - 3.47
Low:	3.07 - 3.08	3.08 - 3.09
Close:	3.41 - 3.43	3.43 - 3.45

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.

Mon, 01 Apr 2024
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sun, 10 Mar 2024
Reviewing Biostage (OTCMKTS:BSTG) and LENSAR (NASDAQ:LNSR) - American Banking and Market News

Thu, 07 Mar 2024
LENSAR, Inc. (NASDAQ:LNSR) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

Mon, 04 Mar 2024
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - Yahoo Finance

Mon, 04 Mar 2024
LENSAR Inc. (LNSR) Reports 18% Revenue Growth in Q4, Surpasses ALLY System Targets - The Tokenist

Fri, 01 Mar 2024
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	11 (M)
Shares Float	8 (M)
Held by Insiders	17.4 (%)
Held by Institutions	41.9 (%)
Shares Short	77 (K)
Shares Short P.Month	52 (K)

EPS	-1.31
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.95
Profit Margin	-34.2 %
Operating Margin	-35.8 %
Return on Assets (ttm)	-13.6 %
Return on Equity (ttm)	-32.3 %
Qtrly Rev. Growth	18.2 %
Gross Profit (p.s.)	0
Sales Per Share	3.69
EBITDA (p.s.)	-0.89
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-2.62
PEG Ratio	0
Price to Book value	1.16
Price to Sales	0.92
Price to Cash Flow	-4.05

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.